Table 2.
Ongoing clinical trials testing radiotherapy combined with chemotherapy in non-indolent, localized prostate cancer.
| Agent | Study phase | Title | Protocol ID |
|---|---|---|---|
| Cabazitaxel | I | Cabazitaxel with radiation and hormone therapy for prostate cancer | NCT01420250 |
| Cabazitaxel | II | Cabazitaxel and radiation for patients with pathologically determined Stage 3 prostate cancer and/or patients with PSA elevation (>0.1 to <2.0 ng/mL) | NCT01650285 |
| Docetaxel | II | The ELDORADO (Eligard®, docetaxel, and radiotherapy) study | NCT00452556 |
| Docetaxel | III | Treatment of prostate cancer with docetaxel + hormonal treatment vs. hormonal treatment in patients treated with radical radiotherapy (AdRad) | NCT00653848 |
| Docetaxel | I/II | Postoperative radiation therapy, hormonal therapy, and concurrent docetaxel for high risk pathologic T2-T3N0 prostate cancer | NCT00669162 |
| Docetaxel | II | Docetaxel, androgen deprivation, and proton therapy for high-risk prostate cancer | NCT01040624 |
| Docetaxel | II | Docetaxel + prednisone with or without radiation for castrate-resistant prostate cancer | NCT01087580 |
| Docetaxel | III | Androgen suppression therapy and radiation therapy with or without docetaxel in treating patients with high-risk localized prostate cancer | NCT00651326 |
| Docetaxel | III | Hormone therapy plus radiation therapy with or without combination chemotherapy in treating patients with prostate cancer | NCT00004054 |
| Docetaxel | III | Hormone suppression and radiation therapy for 6 months with/without docetaxel for high-risk prostate cancer | NCT00116142 |
| Docetaxel | III | Hormone therapy with or without docetaxel and estramustine in treating patients with prostate cancer that is locally advanced or at high risk of relapse | NCT00055731 |
| Ixabepilone | I/II | Radiation therapy and ixabepilone in treating patients with high-risk stage III prostate cancer after surgery | NCT01079793 |